Project Grant R01HL184333
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $635K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Winter Hill, MA 02145, USA
Similar Awards
- The National Institutes of Health National Heart Lung and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $781,860 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the novel role of neutrophils in mediating endothelial regeneration and vascular repair in sepsis and acute respiratory distress syndrome (ARDS). The research addresses ARDS pathology, specifically endothelial barrier injury and increased vascular...
- The National Heart, Lung, and Blood Institute awarded The Washington University $1.902 million on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and correct immune-epithelial pathways underlying chronic muco-obstructive lung disease triggered by viral infection, allergen, smoke, or pollution exposure. The research identifies and characterizes a distinct subset of basal epithelial stem cells (basal-ESCs) that drive muco-obstructive disease phenotypes...
- The National Heart, Lung, and Blood Institute awarded $448,250 to The Research Foundation For The State University Of New York on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and evaluate a lung-targeted immunomodulatory messenger RNA therapy for acute respiratory distress syndrome. The award funds development of an IL-10 mRNA therapeutic delivered via sulfonium lipid nanoparticles, a novel lung-targeting technology designed to suppress...
- The National Heart, Lung, and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $778,202 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research targeting inflammaging-induced endothelial injury and acute respiratory distress syndrome (ARDS) development in aging lungs. The research investigates how aging influences endothelial barrier injury mechanisms in ARDS, with focus on endothelial NADPH oxidase 2 (NOX2)...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Washington University $761,782 under the Cardiovascular Diseases Research program (CFDA 93.837) beginning September 1, 2025, with completion targeted for July 31, 2029. This project grant funds basic and translational research investigating the loss of cilia maintenance mechanisms in acquired and genetic lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The...
- The National Heart, Lung, and Blood Institute awarded Duke University $2,023,862 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837, Assistance Listing R01HL170175) to develop and validate predictive models of acute respiratory distress syndrome (ARDS) using protein biomarkers and clinical data, and to identify resilience markers and endotypes associated with ARDS recovery through an integrated multiomics pipeline. The project, titled "Resilience...
- The National Heart, Lung, and Blood Institute awarded The Washington University $169,140 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support immuno-metabolic research into chronic rejection after lung transplant. The funding supports investigation of the mechanistic drivers of bronchiolitis obliterans syndrome (BOS), a form of chronic rejection that is the major cause of death one year after lung transplant. The principal investigator, a lung transplant...
- The National Heart, Lung, and Blood Institute awarded The Washington University $233,250 under the Cardiovascular Diseases Research program (CFDA 93.837) on June 15, 2026, to investigate the mechanisms by which mycophenolic acid (MPA) induces neutropenia in lung transplant recipients. The research examines how MPA influences neutrophil development, survival, and effector function, with a hypothesis that MPA disrupts metabolic pathways—particularly glycolysis—and alters gene expression during...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $1,541,783 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate novel roles of the thrombin receptor protease-activated receptor-1 (PAR1) in lung lymphatic function and acute respiratory distress syndrome. The research uses mouse models to examine PAR1's role in button junction formation during lung injury. The work identifies how...
- The National Heart, Lung, and Blood Institute awarded The Washington University $680,379 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of sphingolipid biosynthesis during lung infection, specifically examining how SPTLC2, an essential enzyme subunit in sphingolipid synthesis, affects survival during Mycobacterium tuberculosis infection in CD11C+ lung macrophages and dendritic cells. The project addresses immune response mechanisms...